CanSino Biologics Inc. (CASBF)
CASBF Stock Price Chart
Explore CanSino Biologics Inc. interactive price chart. Choose custom timeframes to analyze CASBF price movements and trends.
CASBF Company Profile
Discover essential business fundamentals and corporate details for CanSino Biologics Inc. (CASBF) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
2 Jan 2020
Employees
1.11K
Website
https://www.cansinotech.comCEO
Xuefeng Yu
Description
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It also develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. Further, the company develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. In addition, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CSB012 to treat adenovirus; CSB013 for ZIKA virus; CSB015 to treat meningitis; CSB016 for treating shingles; and CSB107 for polio. CanSino Biologics Inc. was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.
CASBF Financial Timeline
Browse a chronological timeline of CanSino Biologics Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 30 Oct 2025
Revenue estimate is $294.22M.
Earnings released on 20 Aug 2025
EPS came in at -$0.00 surpassing the estimated -$0.01 by +92.31%, while revenue for the quarter reached $33.63M , missing expectations by -90.08%.
Earnings released on 29 Apr 2025
EPS came in at -$0.01 falling short of the estimated -$0.00 by -3.35K%, while revenue for the quarter reached $18.90M .
Earnings released on 25 Mar 2025
EPS came in at -$0.09 falling short of the estimated -$0.08 by -3.50%, while revenue for the quarter reached $38.21M , beating expectations by +0.05%.
Earnings released on 29 Oct 2024
EPS came in at $0.00 surpassing the estimated -$0.05 by +102.88%, while revenue for the quarter reached $37.56M , beating expectations by +21.99%.
Earnings released on 29 Aug 2024
EPS came in at -$0.03 surpassing the estimated -$0.05 by +39.77%, while revenue for the quarter reached $23.55M , missing expectations by -24.12%.
Earnings released on 29 Apr 2024
EPS came in at -$0.10 falling short of the estimated -$0.05 by -110.88%, while revenue for the quarter reached $15.53M , missing expectations by -50.28%.
Earnings released on 21 Feb 2024
EPS came in at -$0.28 falling short of the estimated -$0.20 by -40.47%, while revenue for the quarter reached $25.34M , missing expectations by -5.63%.
Earnings released on 30 Sept 2023
EPS came in at -$0.08 falling short of the estimated -$0.03 by -172.05%, while revenue for the quarter reached $21.15M , beating expectations by +30.13%.
Earnings released on 30 Jun 2023
EPS came in at -$0.39 falling short of the estimated -$0.00 by -36.90K%, while revenue for the quarter reached -$10.97M .
Earnings released on 31 Mar 2023
EPS came in at -$0.08 , while revenue for the quarter reached $14.34M .
Earnings released on 27 Feb 2023
EPS came in at -$1.78 falling short of the estimated $0.72 by -347.22%, while revenue for the quarter reached $47.27M , beating expectations by +149.74%.
Earnings released on 28 Oct 2022
EPS came in at -$0.28 falling short of the estimated $0.84 by -132.84%, while revenue for the quarter reached $10.86M , missing expectations by -76.49%.
Earnings released on 26 Aug 2022
EPS came in at -$0.07 falling short of the estimated $0.73 by -109.03%, while revenue for the quarter reached $19.26M , missing expectations by -79.60%.
Dividend declared on 13 Jul 2022
A dividend of $0.12 per share was announced, adjusted to $0.12. The dividend was paid on 19 Aug 2022.
Earnings released on 28 Apr 2022
EPS came in at $0.08 falling short of the estimated $0.73 by -89.41%, while revenue for the quarter reached $78.36M .
Earnings released on 25 Feb 2022
EPS came in at $2.31 surpassing the estimated $1.92 by +20.31%, while revenue for the quarter reached $190.32M , beating expectations by +0.49%.
Earnings released on 28 Oct 2021
EPS came in at $1.60 falling short of the estimated $2.87 by -44.25%, while revenue for the quarter reached $158.22M .
Earnings released on 27 Aug 2021
EPS came in at $3.85 falling short of the estimated $7.04 by -45.31%, while revenue for the quarter reached $245.97M .
Earnings released on 29 Apr 2021
EPS came in at -$0.06 , while revenue for the quarter reached $70.87M .
Earnings released on 25 Feb 2021
EPS came in at -$0.14 , while revenue for the quarter reached $2.94M .
Earnings released on 27 Oct 2020
EPS came in at -$0.05 , while revenue for the quarter reached $241.93K .
CASBF Stock Performance
Access detailed CASBF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.